By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Zealand Pharma A/S  

Smedeland 26 B

Glostrup    DK-2600  Denmark
Phone: 45-43-28-12-00 Fax: 45-43-28-12-12


SEARCH JOBS








Company News
Zealand Pharma  (ZEAL.CO) Release: Major Shareholder Announcement 7/30/2015 7:01:33 AM
Zealand Pharma  (ZEAL.CO) Release: Major Shareholder Announcement 6/15/2015 8:49:10 AM
Zealand Pharma  (ZEAL.CO) Informs Of Updates Given By Sanofi (SAN.PA) On Lyxumia And Lixilan On An IR Thematic Conference Call On Diabetes 6/9/2015 10:38:33 AM
Zealand Pharma  (ZEAL.CO) Informs That Data Presented From The ELIXA Study Establish Lyxumia As The First GLP-1 Receptor Agonist With Cardiovascular Safety Proven In A Long-Term Outcome Trial 6/9/2015 8:52:34 AM
Presentations On Two Novel Zealand Pharma  (ZEAL.CO) Preclinical Peptide Therapeutics As Possible Approaches For The Treatment Of Type 2 Diabetes And Obesity At The American Diabetes Association's 74th Scientific Sessions 6/8/2015 7:31:15 AM
Zealand Pharma  (ZEAL.CO) Announces That Sanofi (SAN.PA) Has Informed Of Results From Getgoal Duo-2, Showing Advantages Of Lyxumia Versus Rapid-Acting Insulin As Add-On To Lantus For The Treatment Of Type 2 Diabete 6/8/2015 7:29:13 AM
Zealand Pharma  (ZEAL.CO) Increases The Share Capital After Exercise Of Employee Warrants And Announces An Amendment To Its Articles Of Association 6/2/2015 10:32:37 AM
New Data On Lixisenatide (Lyxumia) Including ELIXA Results On Lixilan, And On Novel Zealand Pharma  (ZEAL.CO) Peptide Therapeutics, To Be Presented At The American Diabetes Association's 75th Scientific Sessions 6/2/2015 7:24:23 AM
Zealand Pharma  (ZEAL.CO) Presents To Investors At Four Conferences In June 2015 5/29/2015 11:03:35 AM
Zealand Pharma  (ZEAL.CO) Starts Clinical Development Of A Multiple-Dose Version Of Its Stable Glucagon Analogue, ZP4207 5/20/2015 8:23:19 AM
12345678910...
//-->